Daily treatment with recombinant sRAGE (by intraperitoneal injection) resulted in a reduction in the development of accelerated atherosclerosis in diabetic mice devoid of Apoe, without effects on levels of glucose or lipids. This evidence concerns the gene APOE and atherosclerosis.